New data from the ongoing COMMANDS trial shows Bristol Myers Squibb‘s new myelodysplastic syndrome (MDS) drug, Luspatercept (Reblozyl) may significantly improve anemia in low-risk patients with MDS. The Director of Columbia University’s MDS Center, Dr. Azra Raza, discussed these findings at a recent Case-Based Roundtable event, where the study found that 76.4% of luspatercept-treated patients were able to achieve red blood cell transfusion independence for more than 12 weeks, compared to 55.8% of patients treated with standard erythropoiesis-stimulating agents over the same period. Dr. Raza highlighted luspatercept’s longer-lasting effects, with a median of 155 days to the first post-treatment transfusion compared to 42 days for ESAs.

At OxyDial, we’re encouraged by luspatercept’s potential to transform anemia management in MDS. This research opens new avenues for reducing transfusion dependency and improving the quality of life for patients with this challenging hematological condition.

Read more: https://lnkd.in/eAgxSdrn

hashtag#MDS hashtag#Luspatercept hashtag#Anemia hashtag#BristolMyersSquibb hashtag#HematologyResearch